NASHVILLE, Tenn. – (June 1, 2020) – PathGroup, one of the largest private providers of pathology, clinical and molecular laboratory services in the United States, today announced the availability of a new, minimally-invasive nasal swab collection option as a part of its comprehensive SARS-CoV-2 (COVID-19) testing program.
Many current molecular diagnostic COVID-19 tests rely on a nasopharyngeal (NP) swab, which can cause discomfort for patients during the collection process. The new nasal swab collection option is more comfortable for patients and easier for healthcare providers to administer.
Click here for more information.